1. Home
  2. MREO vs EBF Comparison

MREO vs EBF Comparison

Compare MREO & EBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MREO
  • EBF
  • Stock Information
  • Founded
  • MREO 2015
  • EBF 1909
  • Country
  • MREO United Kingdom
  • EBF United States
  • Employees
  • MREO N/A
  • EBF N/A
  • Industry
  • MREO Biotechnology: Pharmaceutical Preparations
  • EBF Office Equipment/Supplies/Services
  • Sector
  • MREO Health Care
  • EBF Consumer Discretionary
  • Exchange
  • MREO Nasdaq
  • EBF Nasdaq
  • Market Cap
  • MREO 577.6M
  • EBF 613.0M
  • IPO Year
  • MREO N/A
  • EBF N/A
  • Fundamental
  • Price
  • MREO $3.68
  • EBF $20.75
  • Analyst Decision
  • MREO Strong Buy
  • EBF
  • Analyst Count
  • MREO 4
  • EBF 0
  • Target Price
  • MREO $7.50
  • EBF N/A
  • AVG Volume (30 Days)
  • MREO 769.7K
  • EBF 139.5K
  • Earning Date
  • MREO 11-12-2024
  • EBF 12-16-2024
  • Dividend Yield
  • MREO N/A
  • EBF 16.78%
  • EPS Growth
  • MREO N/A
  • EBF N/A
  • EPS
  • MREO N/A
  • EBF 1.57
  • Revenue
  • MREO $1,000,000.00
  • EBF $404,201,000.00
  • Revenue This Year
  • MREO $16.39
  • EBF N/A
  • Revenue Next Year
  • MREO $9.44
  • EBF N/A
  • P/E Ratio
  • MREO N/A
  • EBF $13.17
  • Revenue Growth
  • MREO N/A
  • EBF N/A
  • 52 Week Low
  • MREO $1.86
  • EBF $18.88
  • 52 Week High
  • MREO $5.02
  • EBF $25.75
  • Technical
  • Relative Strength Index (RSI)
  • MREO 39.84
  • EBF 40.22
  • Support Level
  • MREO $3.18
  • EBF $20.53
  • Resistance Level
  • MREO $4.40
  • EBF $20.77
  • Average True Range (ATR)
  • MREO 0.24
  • EBF 0.42
  • MACD
  • MREO -0.06
  • EBF 0.01
  • Stochastic Oscillator
  • MREO 41.39
  • EBF 28.04

About MREO Mereo BioPharma Group plc

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

About EBF Ennis Inc.

Ennis Inc is a manufacturer and supplier of print products for the wholesale trade. The company's products include advertising specialities, business forms and supplies, commercial printing, eCommerce solutions, envelopes, labels and tags, and folders and packaging. Its products include snap sets, continuous forms, laser cut sheets, tags, labels, envelopes, integrated products, jumbo rolls, and pressure-sensitive products in short, medium and long runs under the following labels: Ennis, Royal Business Forms, Block Graphics, 360º Custom LabelsSM, ColorWorx, Enfusion, among others.

Share on Social Networks: